6-MP helps many patients achieve remission in ulcerative colitis. Studies show remission rates ranging from 30-50%, depending on factors like disease severity and patient response. However, it’s not a cure, and maintaining remission often requires ongoing treatment.
Azathioprine (AZA) is a close relative and a common alternative. While they have similar mechanisms of action, AZA is sometimes preferred due to slightly better oral bioavailability in some populations. Your doctor will help determine the best choice for you, considering your individual health profile.
Infliximab, adalimumab, and other biologics represent another category of treatment options. These agents target specific inflammatory pathways, often proving quicker and more potent than 6-MP or AZA for severe disease. Biologics often carry higher costs and increased risk of side effects.
Long-term 6-MP use carries risks, including bone marrow suppression and liver damage. Regular blood tests monitoring blood counts and liver function are vital. Any signs of unusual bruising, bleeding, or fatigue should be reported promptly to your physician. Early detection allows for timely intervention, minimizing potential complications.
The decision to use 6-MP, AZA, or biologics should be a collaborative one between you and your gastroenterologist. They will assess your disease activity, medical history, and tolerance of medications to create the optimal treatment plan. Discuss your concerns and questions openly to ensure informed decision-making.
